---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009249"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:52:10.886900+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics Q1 revenue $0.1M; net loss $7.5M; advancing platform pipeline

## Summary
- Revenue of $0.1M, down from $0.5M YoY due to no grant revenue recognized in Q1 2025.
- Net loss of $7.5M ($0.24 loss per share) compared to net loss of $9.3M ($0.31 per share) in Q1 2024.
- Operating loss improved to $8.6M from $10.3M YoY; operating expenses decreased 18.2%.
- Cash and marketable securities totaled $21.5M as of March 31, 2025.
- On track to begin clinical evaluations for 4 tests and complete India manufacturing facility by year-end 2025.

## SEC filing metadata
- accession: 0001641172-25-009249
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000164117225009249/0001641172-25-009249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000164117225009249/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009249
- JSON: https://secwatch.observer/filing/0001641172-25-009249.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009249.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.